Skip to main content
Viewing from:
Department GEZ-LTA Erasmushogeschool
Intended for healthcare professionals
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by collection
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by collection
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
More
You are viewing from:
Department GEZ-LTA Erasmushogeschool
You are here
Home
Urothelial carcinoma
Email alerts
Urothelial carcinoma
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
Jason
Zhu
,
Andrew J.
Armstrong
,
Terence W.
Friedlander
,
Won
Kim
,
Sumanta K.
Pal
,
Daniel J.
George
,
Tian
Zhang
Journal for ImmunoTherapy of Cancer
Dec 2018,
6
(1)
4;
DOI:
10.1186/s40425-018-0314-1
Urothelial carcinoma of donor origin in a kidney transplant patient
Rosa M.
Michel Ortega
,
Daynna J.
Wolff
,
Cynthia A.
Schandl
,
Harry A.
Drabkin
Journal for ImmunoTherapy of Cancer
Dec 2016,
4
(1)
63;
DOI:
10.1186/s40425-016-0167-4
Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody
Mehmet Asim
Bilen
,
Sumit K.
Subudhi
,
Jianjun
Gao
,
Nizar M.
Tannir
,
Shi-Ming
Tu
,
Padmanee
Sharma
Journal for ImmunoTherapy of Cancer
Dec 2016,
4
(1)
36;
DOI:
10.1186/s40425-016-0139-8
Special collections
COVID-19
(46)
Editor's choice
JITC
Aging and diversity, equity, and inclusion (DEI) with regard to cancer immunotherapy and understudied populations
Aging and diversity, equity, and inclusion (DEI) with regard to cancer immunotherapy and understudied populations
Basic Tumor Immunology
(620)
Cancer Immunotherapy in Understudied Populations
(5)
Case Reports
(192)
Clinical Trials Monitor
(17)
Clinical/Translational Cancer Immunotherapy
(1073)
Commentary/Editorials
(189)
Computational I-O
(6)
COVID-19 and Cancer Immunotherapy
(10)
Emerging Immunotherapeutic Agents
(5)
Guidelines and Consensus Statements
(61)
Guidelines and Consensus Statements
(52)
Imaging and Immunotherapy
(9)
Immune Cell Therapies and Immune Cell Engineering
(302)
Immune Checkpoints - Beyond PD-1
(8)
Immune Checkpoints Beyond PD-1 Series
(8)
Immune Monitoring Technology Primers
(12)
Immunotherapy Biomarkers
(509)
Liquid Biopsies
(8)
Microbial-Based Cancer Immunotherapy
(4)
Oncolytic and Local Immunotherapy
(171)
Reviews
(262)
SITC 40th Anniversary: I-O Progress and Potential
(7)
The Next Wave of Immuno-oncology: A Roadmap from the Society for Immunotherapy of Cancer (SITC)
(1)
Open access
(6900)
Press releases
(6)
